TNDM TANDEM DIABETES CARE INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1438133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.8%
TTM net income YoY75.8%
TTM EPS YoY76.4%
Revenue 3-yr CAGR11.7%
Net income 3-yr CAGR—
Margins
Gross margin56.6%
Operating margin-2.4%
Net margin-4.6%
FCF margin-3.4%
EBITDA margin-0.7%
Returns
ROE-36.7%
ROA-4.8%
ROIC (approx.)-3.9%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets88.3%
Debt / equity4.47x
Current ratio3.21x
Interest coverage-2.80x
Cash quality & payout
Operating cash flow / net income0.30x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $283.69M | $254.56M | $247.22M | $290.38M | $249.25M | $240.68M | $234.42M | $282.65M |
| Cost of revenue | $123.27M | $109.78M | $110.43M | $122.92M | $114.96M | $114.82M | $116.02M | $125.19M |
| Gross profit | $160.42M | $144.78M | $136.79M | $167.46M | $134.29M | $125.86M | $118.41M | $157.46M |
| R&D expense | $48.85M | $46.93M | $46.03M | $46.07M | $48.72M | $48.12M | $50.22M | $52.20M |
| SG&A expense | $113.94M | $111.64M | $108.19M | $113.10M | $108.44M | $109.60M | $113.85M | $105.84M |
| Operating income | -$2.37M | -$13.79M | -$17.43M | $8.29M | -$22.86M | -$51.81M | -$120.88M | -$581,000 |
| Interest expense | $2.31M | $2.45M | $2.20M | $2.08M | $2.06M | $1.91M | $1.86M | $1.86M |
| Pretax income | -$7.69M | -$20.66M | -$19.88M | $4.68M | -$25.14M | -$57.72M | -$122.09M | $16,000 |
| Income tax | -$608,000 | $510,000 | $516,000 | $5.27M | -$3.98M | -$5.32M | $8.47M | -$739,000 |
| Net income | -$7.08M | -$21.17M | -$20.39M | -$589,000 | -$21.16M | -$52.40M | -$130.56M | $755,000 |
| EBITDA | $2.14M | -$9.32M | -$12.93M | $12.79M | -$18.37M | -$47.44M | -$116.57M | $3.66M |
| EPS (basic) | -0.10 | -0.31 | -0.30 | -0.01 | -0.31 | -0.78 | -1.97 | 0.01 |
| EPS (diluted) | -0.10 | -0.31 | -0.30 | -0.01 | -0.31 | -0.78 | -1.97 | 0.01 |
| Weighted avg. shares (diluted) | 69.65M | 69.01M | 68.40M | 68.01M | 67.65M | 67.05M | 66.40M | 66.16M |
| Balance sheet | ||||||||
| Cash & equivalents | $72.84M | $62.82M | $179.32M | $90.63M | $91.95M | $64.11M | $53.57M | $69.23M |
| Short-term investments | $370.24M | $393.18M | $390.93M | $202.03M | $227.16M | $251.25M | $315.05M | $369.10M |
| Receivables | $180.02M | $162.06M | $140.67M | $165.49M | $125.94M | $128.44M | $126.56M | $114.58M |
| Inventory | $143.12M | $135.11M | $126.40M | $128.77M | $137.28M | $142.57M | $141.16M | $149.61M |
| Current assets | $820.72M | $804.64M | $887.10M | $618.14M | $616.94M | $614.82M | $663.43M | $724.49M |
| PP&E, net | $85.14M | $84.50M | $83.25M | $83.58M | $77.92M | $77.51M | $79.22M | $78.15M |
| Intangibles | — | — | — | $11.72M | — | — | — | $925,000 |
| Total assets | $1.16B | $1.15B | $1.15B | $881.11M | $874.65M | $875.74M | $922.14M | $967.66M |
| Current liabilities | $256.07M | $253.00M | $247.96M | $242.72M | $252.54M | $251.69M | $288.18M | $247.05M |
| Short-term debt | — | — | — | — | — | — | — | $40.67M |
| Long-term debt | $603.39M | $602.58M | $601.77M | $310.04M | $309.59M | $309.15M | $308.70M | $308.27M |
| Total debt | $603.39M | $602.58M | $601.77M | $310.04M | $309.59M | $309.15M | $308.70M | $348.94M |
| Total liabilities | $1.02B | $1.02B | $1.02B | $725.94M | $741.69M | $742.45M | $766.85M | $704.56M |
| Shareholders' equity | $135.09M | $130.39M | $132.40M | $155.17M | $132.97M | $133.28M | $155.29M | $263.10M |
| Net debt | $530.55M | $539.76M | $422.44M | $219.40M | $217.64M | $245.03M | $255.13M | $279.70M |
| Shares outstanding | 69.76M | 69.54M | 68.50M | 68.29M | 67.77M | 67.53M | 66.57M | 66.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$819,000 | -$34.63M | $11.05M | $9.79M | $8.26M | -$9.50M | -$18.28M | $10.72M |
| Capital expenditure | $4.69M | $4.05M | $6.27M | $6.68M | $4.09M | $6.21M | $2.96M | $3.07M |
| Free cash flow | -$5.51M | -$38.68M | $4.79M | $3.10M | $4.17M | -$15.70M | -$21.24M | $7.65M |
| Investing cash flow | $17.98M | -$87.34M | -$195.45M | -$14.98M | $20.54M | $58.13M | $9.19M | $5.01M |
| Financing cash flow | -$7.03M | $2.15M | $274.16M | $2.60M | -$1.57M | -$39.71M | -$4.69M | $2.30M |
| Depreciation & amortization | $4.51M | $4.47M | $4.50M | $4.50M | $4.49M | $4.37M | $4.31M | $4.25M |
| Stock-based compensation | $15.90M | $15.74M | $15.66M | $20.11M | $21.14M | $25.64M | $25.49M | $28.17M |
| Share buybacks | — | — | — | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.